Treatment of immunodeficiency with interleukin-2: initial exploration

Area of Science:

• Immunology
• Biotechnology

Background:

• Patients with acquired immunodeficiency syndrome (AIDS), lymphoma, or severe combined immunodeficiency often exhibit impaired T cell function.
• Mitogen-induced T cell proliferation is a key indicator of immune system health.

Purpose of the Study:

• To evaluate the safety and potential efficacy of highly purified interleukin-2 (IL-2) in patients with various immunodeficiency states.
• To assess the impact of IL-2 on ex vivo T cell proliferation defects.

Main Methods:

• Fifteen patients received highly purified human lymphocyte-derived IL-2 via subcutaneous injection or continuous infusion.
• Dosing ranged up to 20,000 U/m2 daily, with a maximum total dose of 855,000 U/m2 over 77 days.
• T cell proliferation was assessed in vitro with and without IL-2 addition.

Main Results:

• IL-2 partially corrected in vitro mitogen-induced T cell proliferation defects in all treated patients.
• One patient with AIDS showed an increased platelet count.
• Another AIDS patient experienced a decrease in monoclonal immunoglobulin levels, and a lymphoma patient had a minor tumor response.
• No significant toxicity was observed during the treatment period.

Conclusions:

• Highly purified IL-2 demonstrated a capacity to partially restore T cell function in immunodeficient patients.
• The observed biological effects and lack of toxicity support further research into IL-2 for human immunodeficiency treatment.
• IL-2 represents a potential therapeutic agent for immune system enhancement in specific patient populations.